New research reveals that people who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop conventional diet and exercise programs.
Research printed in a major medical journal shows that while overweight people can lose substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these drugs should be informed of the danger of fast weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a reversion to pre-treatment weight within about one and a half years.
Analyzing Therapies
The study, which looked at dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers point out that people who lose weight through diet and exercise typically have a less rapid weight regain—around 100 grams monthly—post-intervention.
The Reason for the Rapid Regain
Experts propose the way of the jabs accounts for the accelerated regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to hunger is no longer kept in check, making overeating much more probable."
A Lifelong Condition?
The NHS advise the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, given the high risk of relapse, the therapy is often life-long.
This perspective is supported by drug manufacturers, who state that the findings "emphasize the chronic character of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the medication describe a sudden resurgence of cravings.
"It was like a trigger that goes on and you're instantly starving," said one woman.
This difficulty is compounded if patients have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are effective agents for weight loss, they are not a magic fix and long-term success hinges on combined behavioural changes.
